265 related articles for article (PubMed ID: 34651242)
1. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
4. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
[TBL] [Abstract][Full Text] [Related]
5. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.
Triggiani L; Mazzola R; Magrini SM; Ingrosso G; Borghetti P; Trippa F; Lancia A; Detti B; Francolini G; Matrone F; Bortolus R; Fanetti G; Maranzano E; Pasqualetti F; Paiar F; Bonù ML; Magli A; Bruni A; Mazzeo E; Franzese C; Scorsetti M; Alongi F; Jereczek-Fossa BA; Ost P; Buglione M
World J Urol; 2019 Dec; 37(12):2631-2637. PubMed ID: 30859273
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiotherapy to oligoprogressive lesions detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
[TBL] [Abstract][Full Text] [Related]
7. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis.
Deodato F; Pezzulla D; Cilla S; Ferro M; Romano C; Bonome P; Buwenge M; Zamagni A; Strigari L; Valentini V; Morganti AG; Macchia G
Clin Transl Oncol; 2022 Jun; 24(6):1177-1183. PubMed ID: 34984604
[TBL] [Abstract][Full Text] [Related]
9. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
Muldermans JL; Romak LB; Kwon ED; Park SS; Olivier KR
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):696-702. PubMed ID: 27131082
[TBL] [Abstract][Full Text] [Related]
11. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D
Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
Valeriani M; Detti B; Fodor A; Caini S; Borghesi S; Trippa F; Triggiani L; Bruni A; Russo D; Saldi S; Di Staso M; Francolini G; Lancia A; Marinelli L; Di Muzio N; Aristei C; Livi L; Magrini SM; Ingrosso G
Radiol Med; 2022 Jan; 127(1):108-116. PubMed ID: 34748151
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
Ingrosso G; Trippa F; Maranzano E; Carosi A; Ponti E; Arcidiacono F; Draghini L; Di Murro L; Lancia A; Santoni R
World J Urol; 2017 Jan; 35(1):45-49. PubMed ID: 27233779
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
17. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.
Jereczek-Fossa BA; Fanetti G; Fodor C; Ciardo D; Santoro L; Francia CM; Muto M; Surgo A; Zerini D; Marvaso G; Timon G; Romanelli P; Rondi E; Comi S; Cattani F; Golino F; Mazza S; Matei DV; Ferro M; Musi G; Nolè F; de Cobelli O; Ost P; Orecchia R
Clin Genitourin Cancer; 2017 Aug; 15(4):e623-e632. PubMed ID: 28185875
[TBL] [Abstract][Full Text] [Related]
18. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
20. The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy.
Davis JN; Medbery C; Sharma S; Danish A; Mahadevan A
Radiat Oncol; 2013 Nov; 8():275. PubMed ID: 24274599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
